Turn Therapeutics (Nasdaq: TTRX), a clinical-stage biotechnology company focused on developing first-in-class targeted therapies for inflammatory skin diseases, visits the Nasdaq MarketSite in Times Square. Its innovative approach centers on localized, non-systemic treatments designed to deliver effective therapeutic impact where disease occurs while reducing unnecessary systemic exposure. 

In honor of the occasion, Bradley Burnam, Founder & CEO, rings the Closing Bell.